论文部分内容阅读
DcR3(decoy receptor3,诱骗受体3),也称之为TR6,是20世纪末才发现的新的肿瘤坏死因子受体。DcR3不仅能够竞争性结合Fas配体、T细胞上可诱导表达的,与单纯疱疹病毒糖蛋白D竞争结合单纯疱疹病毒侵入介体的淋巴毒素类似物(homologous to lymphotoxins shows inducible expression and competes with HSV glycoprotein D for herpes virus entry mediator,a receptor expressed by T lymphocytes, LIGHT)、TNF和IL-1α诱导表达的肿瘤坏死因子样配体1A(,TL1A),从而发挥抗凋亡作用,而且还能调控免疫
DcR3 (decoy receptor3), also known as TR6, is a new tumor necrosis factor receptor discovered in the late 20th century. DcR3 is not only capable of competitively binding to Fas ligand, homologous to lymphotoxins shows inducible expression and competes with HSV glycoprotein that is inducibly expressed on T cells that competes with herpes simplex virus glycoprotein D for binding to herpes simplex virus invaded mediators D for herpes virus entry mediator, a receptor expressed by T lymphocytes, LIGHT), tumor necrosis factor-like ligand 1A (, TL1A) induced by TNF and IL-1α to exert anti-apoptotic effects,